20September

Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and bod ... Read more

18September

Novo Nordisk announces plans to transform its approach to Research & Development ... Read more

20August

Oral semaglutide provides superior HbA1c and weight reductions versus placebo in ... Read more

17August

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose respons ... Read more

20September

Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and bod ... Read more

17September

Novo Nordisk A/S - Share repurchase programme ... Read more

10September

Novo Nordisk A/S - Share repurchase programme ... Read more

03September

Novo Nordisk A/S - Share repurchase programme ... Read more

25September

Carnegie Diabetes Seminar, Copenhagen

27September

Bernstein Strategic Decisions Conference, London

27September

JP Morgan Milan Investor Forum, Milan

01October

Silent period,

01October

EASD Annual Congress, Berlin

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Annual Report 2017 


Click here to find further information

 
Q2 2018 financial results


Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.


ADA investor and analyst event